The Global Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Market size is expected to reach $11.9 billion by 2028, rising at a market growth of 16.3% Compound Annal Growth Rate (CAGR) during the forecast period, according to a report published by Research and Markets.

The report, “Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product, By Phase, By Regional Outlook and Forecast, 2022-2028” states that there is a rising need for CDMOS because of the increasing number of Advanced Therapy Medicinal Products (ATMP) clinical trials.

According to a study by the American Society of Gene and Cell Therapy, there were 3,579 gene, cell, and RNA therapies in development as of Q1 2022.

Researchers found that as of Q1 2021, the pipeline for gene cell therapy has grown by 16%.

In addition, genetically engineered cell therapies are being outperformed in the pipeline by CAR-T cell therapies.

Furthermore, 98% of CAR-T cell treatments are still being developed for cancer-related indications. All these factors, according to researchers, influence an increase in the number of CDMO and promote the growth of the advanced therapy medicinal products CDMO market. 

According to the report, it is projected that America will maintain its position as a leader in R&D for cutting-edge treatments in the coming years.